Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

4 Nov 2022

Abstract excerpt

Myelodysplastic syndromes (MDS) are a myeloid neoplasm characterized by clonal hematopoiesis, peripheral cytopenias, and morphologic dysplasia with a tendency to progress to acute myeloid leukemia. Current therapies are tailored based on disease risk using the Revised International Prognostic System (IPSS-R) complemented by molecular data and patient-related factors [ 1 , 2 ]. The standards of care for high risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36329025
DOI: 10.1038/s41408-022-00744-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromePMID 36329025Read ↗

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeSemantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patientsSemantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched studySemantic proximity Read ↗

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromesSemantic proximity Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.